Chad Huff
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Germline variants and somatic mutations in homologous recombination pathway genes prioritized in the 2020 American Society of Clinical Oncology (ASCO) recommendation for genetic testing in ovarian cancer
Year:
2025
Background: Half of ovarian high-grade serous carcinomas (HGSC) have homologous recombination deficiency (HRD). However, HRD is not well characterized in Black individuals who experience worse survival after a diagnosis of HGSC. The objective of this study was to characterize ovarian HGSC HRD and examine its association with survival by self-reported race. Methods: HRD features were identified using matched tumor–normal whole-exome and RNA sequencing in an HGSC cohort. We calculated age- and stage-adjusted HR and 95% confidence intervals (CI) for survival, comparing individuals with a feature to those without, separately by self-reported race. Results: Any HRD was associated with a 32% reduced risk of death in Black individuals compared with a 62% reduction in White individuals (Black HR = 0.68; 95% CI, 0.43–1.09; White HR = 0.38; 95% CI, 0.14–1.04). More of the germline and somatic variants detected among Black individuals were unannotated or variants of uncertain significance (VUS; germline 65% vs. 45%; somatic 62% vs. 50%). Black individuals with germline unannotated/VUS were more likely to have tumors with HRD scarring and a first-degree family history of breast or ovarian cancer compared with those without (HRD scar 71.4% vs. 49.6%; family history 68.4% vs. 34.6%). Conclusions: HRD testing informs precision-based medicine approaches that improve outcomes, but a higher proportion of VUS among Black individuals may complicate referral for such care leading to worse outcomes for Black individuals. Impact: Our findings emphasize the importance of recruiting diverse individuals in genomics research and better characterizing VUS.
Year:
2025
Black individuals experience worse survival after a diagnosis of high-grade serous ovarian carcinoma (HGSC) than White individuals and are underrepresented in ovarian cancer research. To date, the understanding of the molecular and genomic heterogeneity of HGSC is based primarily on the evaluation of tumors from White individuals. In the present study, we performed whole-exome sequencing on HGSC samples from 211 Black patients to identify significantly mutated genes and characterize mutational signatures, assessing their distributions by gene expression subtypes. The occurrence and frequency of somatic mutations and signatures by self-reported race were compared with historic data from The Cancer Genome Atlas (TCGA). Despite technical differences (e.g., formalin-fixed vs. fresh-frozen tissue), the distribution of mutations and their variant classifications for major HGSC genes were nearly identical across study populations. However, de novo significantly mutated gene analysis identified genes not previously reported in TCGA analysis, including the oncogene KRAS and the potential tumor suppressor OBSCN . The prevalence of the homologous recombination deficiency signature was higher among Black individuals with the immunoreactive gene expression subtype compared with the mesenchymal and proliferative subtypes. These findings were confirmed by comparing the data from Black patients with those from 123 White patients with identical tissue collection and processing. Overall, this study suggests that, although most features of HGSC tumor phenotypes are similar in Black and White populations, there may be clinically relevant differences. If validated, these phenotypes may be important for clinical decision-making and would have been missed by characterizing tumors from White individuals only. Significance: Elucidation of the somatic mutational landscape of high-grade serous ovarian carcinoma in Black individuals, who experience poor survival and are underrepresented in research, could inform patient prognosis and enable precision medicine opportunities.
Year:
2025
Percentage of the population with mutations in HGSC genes in major HGSC genes identified in TCGA, genes identified by de novo significantly mutated gene analysis in SchildkrautB, or mutated in ≥4% of SchildkrautB, by gene expression subtype
Year:
2025
Integrating genome-wide association study (GWAS) and transcriptomic datasets can help identify mediators for genetic risk of cancer. Traditional methods often are insufficient as they rely on total gene expression measures and overlook alternative splicing, which generates different transcript-isoforms with potentially distinct effects. Here, we integrate multi-tissue isoform expression data from the Genotype Tissue-Expression Project with GWAS summary statistics (all N > 20,000 cases) to identify isoform- and gene-level associations with six cancers (breast, endometrial, colorectal, lung, ovarian, prostate) and six related cancer subtype classifications (N = 12 total). Directly modeling isoforms using transcriptome-wide association studies (isoTWAS) significantly improves discovery of genetic associations compared to gene-level approaches, identifying 164% more significant associations (6,163 vs. 2,336) with isoTWAS-prioritized genes enriched 4-fold for evolutionarily-constrained genes. isoTWAS tags transcriptomic associations at 52% more independent GWAS loci across the six cancers. Isoform expression mediates an estimated 63% greater proportion of cancer risk SNP heritability compared to gene expression. We highlight several isoTWAS associations that demonstrate GWAS colocalization at the isoform level but not at the gene level, including CLPTM1L (lung cancer), LAMC1 (colorectal), and BABAM1 (breast). These results underscore the importance of modeling isoforms to maximize discovery of genetic risk mechanisms for cancers.
Year:
2024
Supplementary Figure S7. Major immune cell types derived from bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (S) and Unsatisfactory (US) groups.
Year:
2024
Supplementary Figure S8. Heatmap showing immune-related Level 1 Reactome and selected Cancer Hallmark pathways in bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (n=27) and Unsatisfactory (n=13) groups.
Year:
2024
Supplementary Figure S11. Proportions of patients with AVPCmDNA and genomic alterations in p53, RB1, and PTEN in each group based on WES of metastatic tumor biopsies from patients in the Satisfactory group (n=37, in red) and in the Unsatisfactory group (n=22, in blue).
Year:
2024
Purpose: To determine the efficacy and safety of risk-adapted combinations of androgen signaling inhibitors and inform disease classifiers for metastatic castration–resistant prostate cancers. Patients and Methods: In a modular, randomized phase II trial, 192 men were treated with 8 weeks of abiraterone acetate, prednisone, and apalutamide (AAPA; module 1 ) and then allocated to modules 2 or 3 based on satisfactory (≥50% PSA decline from baseline and unsatisfactory status. Men in the former were randomly assigned to continue AAPA alone ( module 2A ) or with ipilimumab ( module 2B ). Men in the latter group had carboplatin + cabazitaxel added to AAPA ( module 3 ). Optional baseline biopsies were subjected to correlative studies. Results: Median overall survival (from allocation) was 46.4 [95% confidence interval (CI), 39.2–68.2], 41.4 (95% CI, 33.3–49.9), and 18.7 (95% CI, 14.3–26.3) months in modules 2A ( n = 64), 2B ( n = 64), and 3 ( n = 59), respectively. Toxicities were within expectations. Of 192 eligible patients, 154 (80.2%) underwent pretreatment metastatic biopsies. The aggressive - variant prostate cancer molecular profile (defects in ≥2 of p53, RB1, and PTEN) was associated with unsatisfactory status. Exploratory analyses suggested that secreted phosphoprotein 1–positive and insulin-like growth factor–binding protein 2–positive macrophages, druggable myeloid cell markers, and germline pathogenic mutations were enriched in the unsatisfactory group. Conclusions: Adding ipilimumab to AAPA did not improve outcomes in men with androgen-responsive metastatic castration–resistant prostate cancer. Despite the addition of carboplatin + cabazitaxel, men in the unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.
Year:
2024
Purpose: To determine the efficacy and safety of risk-adapted combinations of androgen signaling inhibitors and inform disease classifiers for metastatic castration–resistant prostate cancers. Patients and Methods: In a modular, randomized phase II trial, 192 men were treated with 8 weeks of abiraterone acetate, prednisone, and apalutamide (AAPA; module 1 ) and then allocated to modules 2 or 3 based on satisfactory (≥50% PSA decline from baseline and unsatisfactory status. Men in the former were randomly assigned to continue AAPA alone ( module 2A ) or with ipilimumab ( module 2B ). Men in the latter group had carboplatin + cabazitaxel added to AAPA ( module 3 ). Optional baseline biopsies were subjected to correlative studies. Results: Median overall survival (from allocation) was 46.4 [95% confidence interval (CI), 39.2–68.2], 41.4 (95% CI, 33.3–49.9), and 18.7 (95% CI, 14.3–26.3) months in modules 2A ( n = 64), 2B ( n = 64), and 3 ( n = 59), respectively. Toxicities were within expectations. Of 192 eligible patients, 154 (80.2%) underwent pretreatment metastatic biopsies. The aggressive - variant prostate cancer molecular profile (defects in ≥2 of p53, RB1, and PTEN) was associated with unsatisfactory status. Exploratory analyses suggested that secreted phosphoprotein 1–positive and insulin-like growth factor–binding protein 2–positive macrophages, druggable myeloid cell markers, and germline pathogenic mutations were enriched in the unsatisfactory group. Conclusions: Adding ipilimumab to AAPA did not improve outcomes in men with androgen-responsive metastatic castration–resistant prostate cancer. Despite the addition of carboplatin + cabazitaxel, men in the unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (18)
Tabitha Harrison
Fred Hutchinson Cancer Research Center
Lucas A Salas
Assistant Professor
Dartmouth College Geisel School of Medicine
Christopher J. Logothetis
The University of Texas MD Anderson Cancer Center
Lindsay J Collin
Assistant Professor
Emory University
Paul Corn
Chair
The University of Texas MD Anderson Cancer Center
Joellen Schilkdraut
Professor
Emory University
James P. Allison
Professor and Chair
The University of Texas MD Anderson Cancer Center
Casey Greene
Director
University of Colorado Anschutz Medical Campus
Paul Viscuse
Assistant Professor
University of Virginia
Miao Zhang
Assistant Professor
The University of Texas MD Anderson Cancer Center
Ana Aparicio
Professor
The University of Texas MD Anderson Cancer Center
Sumit Subudhi
Assistant Professor
The University of Texas MD Anderson Cancer Center
Arjun Bhattacharya
Assistant Professor
The University of Texas MD Anderson Cancer Center
Jennifer Anne Doherty
Professor
University of Utah
Taylor Head
The University of Texas MD Anderson Cancer Center
Natalie Davidson
Assistant Professor
University of Colorado Anschutz Medical Campus
Yung-Han Chang
The University of Texas MD Anderson Cancer Center
Wenyi Wang
Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.